{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:31:29Z","timestamp":1789115489163,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019870","name":"Cancer Foundation of China","doi-asserted-by":"publisher","award":["2022CR72"],"award-info":[{"award-number":["2022CR72"]}],"id":[{"id":"10.13039\/501100019870","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019870","name":"Cancer Foundation of China","doi-asserted-by":"publisher","award":["CFCMYZLKYJJ011"],"award-info":[{"award-number":["CFCMYZLKYJJ011"]}],"id":[{"id":"10.13039\/501100019870","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273350"],"award-info":[{"award-number":["82273350"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20460"],"award-info":[{"award-number":["U23A20460"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017415","name":"Peking University First Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017415","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.tranon.2026.102836","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:07:15Z","timestamp":1780607235000},"page":"102836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prediction of immune-related adverse events in urological cancer during checkpoint inhibitor immunotherapy through immunohistochemical analysis of tumorous LCP1\/ADPGK"],"prefix":"10.1016","volume":"70","author":[{"given":"Liqing","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiceng","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninghan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6254-7196","authenticated-orcid":false,"given":"Yaqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.tranon.2026.102836_bib0001","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.tranon.2026.102836_bib0002","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"issue":"1","key":"10.1016\/j.tranon.2026.102836_bib0003","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41571-023-00826-2","article-title":"Progress in systemic therapy for advanced-stage urothelial carcinoma","volume":"21","author":"Nadal","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10064","key":"10.1016\/j.tranon.2026.102836_bib0004","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.tranon.2026.102836_bib0005","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1093\/annonc\/mdx518","article-title":"Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study","volume":"28","author":"Necchi","year":"2017","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.tranon.2026.102836_bib0006","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.tranon.2026.102836_bib0007","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.tranon.2026.102836_bib0008","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.tranon.2026.102836_bib0009","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"36","key":"10.1016\/j.tranon.2026.102836_bib0010","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"10236","key":"10.1016\/j.tranon.2026.102836_bib0011","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.tranon.2026.102836_bib0012","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with Anti-PD-1 therapy for advanced non-small cell lung cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol."},{"issue":"69","key":"10.1016\/j.tranon.2026.102836_bib0013","doi-asserted-by":"crossref","first-page":"114268","DOI":"10.18632\/oncotarget.23217","article-title":"Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors","volume":"8","author":"Diehl","year":"2017","journal-title":"Oncotarget."},{"issue":"4","key":"10.1016\/j.tranon.2026.102836_bib0014","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/CJI.0000000000000415","article-title":"Association of blood biochemical indexes and antibiotic exposure with severe immune-related adverse events in patients with advanced cancers receiving PD-1 inhibitors","volume":"45","author":"Zhao","year":"2022","journal-title":"J. Immunother"},{"issue":"1","key":"10.1016\/j.tranon.2026.102836_bib0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41416-018-0155-1","article-title":"Immune dysregulation in cancer patients developing immune-related adverse events","volume":"120","author":"Khan","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.tranon.2026.102836_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.tranon.2026.102836_bib0017","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1002\/cam4.4675","article-title":"Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: a prospective longitudinal pan-cancer study","volume":"11","author":"Barth","year":"2022","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.tranon.2026.102836_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004008","article-title":"Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition","volume":"10","author":"Ghosh","year":"2022","journal-title":"J. Immunother Cancer."},{"issue":"4","key":"10.1016\/j.tranon.2026.102836_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70721","article-title":"Peripheral blood mononuclear cells profiling revealed biomarkers that predict PD-1 inhibitor-induced immune-related adverse events","volume":"7","author":"Wang","year":"2026","journal-title":"MedComm"},{"key":"10.1016\/j.tranon.2026.102836_bib0020","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejca.2020.02.049","article-title":"Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency","volume":"130","author":"Yano","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tranon.2026.102836_bib0021","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","article-title":"Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors","volume":"107","author":"Hasan Ali","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.tranon.2026.102836_bib0022","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41591-022-01698-2","article-title":"Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1","volume":"28","author":"McCulloch","year":"2022","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.tranon.2026.102836_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102361","article-title":"Monogenic lupus: dissecting heterogeneity","volume":"18","author":"Omarjee","year":"2019","journal-title":"Autoimmun. Rev."},{"issue":"10","key":"10.1016\/j.tranon.2026.102836_bib0024","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/s41416-018-0074-1","article-title":"Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients","volume":"118","author":"Bins","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2026.102836_bib0025","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1038\/s41467-020-18742-9","article-title":"Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy","volume":"11","author":"Jing","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102836_bib0026","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.jaci.2024.05.001","article-title":"L-plastin associated syndrome of immune deficiency and hematologic cytopenia","volume":"154","author":"Hernandez","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102836_bib0027","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50566-6","article-title":"ADP-dependent glucokinase regulates energy metabolism via ER-localized glucose sensing","volume":"9","author":"Imle","year":"2019","journal-title":"Sci. Rep."},{"issue":"16","key":"10.1016\/j.tranon.2026.102836_bib0028","doi-asserted-by":"crossref","first-page":"9331","DOI":"10.1073\/pnas.95.16.9331","article-title":"A role for the actin-bundling proteinL-plastin in the regulation of leukocyte integrin function","volume":"95","author":"Jones","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U S. A"},{"issue":"11","key":"10.1016\/j.tranon.2026.102836_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110507","article-title":"L-plastin enhances NLRP3 inflammasome assembly and bleomycin-induced lung fibrosis","volume":"38","author":"Joshi","year":"2022","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.tranon.2026.102836_bib0030","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1074\/jbc.M115.679902","article-title":"The structural and functional characterization of mammalian ADP-dependent glucokinase","volume":"291","author":"Richter","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.tranon.2026.102836_bib0031","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1186\/s12885-025-14007-0","article-title":"Evaluation of tumorous LCP1 and ADPGK as predictive biomarker for immune-related adverse events in bone and soft tissue sarcomas treated with anti-PD-1 and anti-PD-L1 antibodies","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC. Cancer"},{"issue":"6","key":"10.1016\/j.tranon.2026.102836_bib0032","first-page":"12","article-title":"Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision","author":"Emens","year":"2024","journal-title":"J. Immunother Cancer."},{"key":"10.1016\/j.tranon.2026.102836_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114235","article-title":"Immunotherapy efficacy and toxicity: reviewing the evidence behind patient implementable strategies","volume":"209","author":"Verhaert","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.tranon.2026.102836_bib0034","first-page":"16","article-title":"Non-invasive predictive biomarkers for immune-related adverse events due to immune checkpoint inhibitors","author":"Ponvilawan","year":"2024","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.tranon.2026.102836_bib0035","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.62347\/MWLI5585","article-title":"Predicting immunotherapy-related adverse events in late-stage non-small cell lung cancer with KARS G12C mutation treated with PD-1 inhibitors through combined assessment of LCP1 and ADPGK expression levels","volume":"14","author":"Chen","year":"2024","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102836_bib0036","article-title":"Predictive value of LCP1 and ADPGK for immune-related adverse events across multiple cancer types in patients receiving immunotherapy-based regimens","author":"Zhang","year":"2026","journal-title":"Acta Biochim. Biophys. Sin."},{"issue":"1","key":"10.1016\/j.tranon.2026.102836_bib0037","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/imr.12102","article-title":"The actin-bundling proteinl-plastin supports T-cell motility and activation","volume":"256","author":"Morley","year":"2013","journal-title":"Immunol. Rev."},{"issue":"5","key":"10.1016\/j.tranon.2026.102836_bib0038","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.celrep.2012.10.009","article-title":"T cell activation is driven by an ADP-dependent glucokinase linking enhanced glycolysis with mitochondrial reactive oxygen species generation","volume":"2","author":"Kaminski","year":"2012","journal-title":"Cell Rep."},{"key":"10.1016\/j.tranon.2026.102836_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121091","article-title":"Co-assembled nanocomplexes of peptide neoantigen Adpgk and toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy","volume":"608","author":"Liang","year":"2021","journal-title":"Int. J. Pharm."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326001737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326001737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:40:39Z","timestamp":1789112439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326001737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":39,"alternative-id":["S1936523326001737"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102836","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of immune-related adverse events in urological cancer during checkpoint inhibitor immunotherapy through immunohistochemical analysis of tumorous LCP1\/ADPGK","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102836","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102836"}}